Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the best hot stocks to invest in. On October 6, Raymond James raised the firm’s price target on Monopar Therapeutics to $142 from$80, while keeping a Strong Buy rating on the shares. The firm thinks that the company’s shares can continue to work well into 2026. Earlier in Q2 2025, the company’s net loss was $2.5 million (or$0.35 per share), compared to a net loss of $1.7 million (or$0.49 per share) for Q2 2024. Monopar Therapeutics reported that its cas ...